0.4736
price down icon3.35%   -0.0164
after-market After Hours: .48 0.0064 +1.35%
loading
Aditxt Inc stock is traded at $0.4736, with a volume of 865.46K. It is down -3.35% in the last 24 hours and down -70.40% over the past month. Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.49
Open:
$0.48
24h Volume:
865.46K
Relative Volume:
0.40
Market Cap:
$4.14M
Revenue:
$749.50K
Net Income/Loss:
$-29.60M
P/E Ratio:
-0.00126
EPS:
-376.0263
Net Cash Flow:
$-22.09M
1W Performance:
-19.15%
1M Performance:
-70.40%
6M Performance:
-99.49%
1Y Performance:
-99.82%
1-Day Range:
Value
$0.4529
$0.4879
1-Week Range:
Value
$0.4529
$0.59
52-Week Range:
Value
$0.4529
$380.00

Aditxt Inc Stock (ADTX) Company Profile

Name
Name
Aditxt Inc
Name
Phone
909-488-0844
Name
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Name
Employee
47
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
ADTX's Discussions on Twitter

Aditxt Inc Stock (ADTX) Latest News

pulisher
04:56 AM

Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance - TipRanks

04:56 AM
pulisher
Nov 01, 2024

ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Aditxt receives positive FDA feedback on ATI-1801 development - Investing.com India

Nov 01, 2024
pulisher
Oct 31, 2024

Evofem Biosciences enters agreements amid merger plans By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 31, 2024

ADTX stock plunges to 52-week low of $0.53 amid market challenges - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 31, 2024

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Appili Therapeutics’ FDA Alignment and Aditxt Acquisition - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

Aditxt Enters Major Investment Agreement with Evofem - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

Aditxt appoints Sylvia Hermina to board By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 29, 2024

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives - Quantisnow

Oct 29, 2024
pulisher
Oct 29, 2024

Aditxt appoints Sylvia Hermina to board - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors - Marketscreener.com

Oct 29, 2024
pulisher
Oct 29, 2024

Evofem Biosciences, Inc. announced that it has received $2.28 million in funding from Aditxt, Inc. - Marketscreener.com

Oct 29, 2024
pulisher
Oct 28, 2024

Is Aditxt Inc (NASDAQ: ADTX) Doomed From The Get-Go? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - Quantisnow

Oct 28, 2024
pulisher
Oct 28, 2024

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem - Quantisnow

Oct 28, 2024
pulisher
Oct 24, 2024

ADTX stock touches 52-week low at $0.89 amid sharp decline - Investing.com UK

Oct 24, 2024
pulisher
Oct 21, 2024

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time - StockTitan

Oct 21, 2024
pulisher
Oct 17, 2024

Aditxt shares sold by major stakeholder HRT Financial for $29,874 - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

ADTX stock touches 52-week low at $1.07 amid steep annual decline - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

ADTX stock touches 52-week low at $1.07 amid steep annual decline By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 16, 2024

Why Aditxt Inc Stock Might Make Sense If Bought Today - Stocks Register

Oct 16, 2024
pulisher
Oct 16, 2024

There is no way Aditxt Inc (ADTX) can keep these numbers up - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Aditxt Inc (ADTX) requires closer examination - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Market Insight: Aditxt Inc (ADTX)’s Notable Drop, Closing at 1.16 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Aditxt Inc: Analyzing ADTX Stock Trends - The InvestChronicle

Oct 14, 2024
pulisher
Oct 12, 2024

Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy - Yahoo Finance

Oct 12, 2024
pulisher
Oct 12, 2024

InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test - MSN

Oct 12, 2024
pulisher
Oct 11, 2024

Aditxt moves to acquire Appili Therapeutics - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Appili Therapeutics Corrects Shareholder Payout Terms - TipRanks

Oct 10, 2024
pulisher
Oct 10, 2024

Aditxt moves to acquire Appili Therapeutics By Investing.com - Investing.com Canada

Oct 10, 2024
pulisher
Oct 10, 2024

Appili Therapeutics – Press Release Correction - GlobeNewswire Inc.

Oct 10, 2024
pulisher
Oct 10, 2024

Appili Therapeutics mails circular in connection with special meeting - TipRanks

Oct 10, 2024
pulisher
Oct 10, 2024

Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval - StockTitan

Oct 10, 2024
pulisher
Oct 10, 2024

Appili Therapeutics Nears Acquisition by Aditxt Inc. - TipRanks

Oct 10, 2024
pulisher
Oct 10, 2024

Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders - The Manila Times

Oct 10, 2024
pulisher
Oct 10, 2024

You might want to take a look at Aditxt Inc (ADTX) now - SETE News

Oct 10, 2024
pulisher
Oct 09, 2024

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time - Quantisnow

Oct 09, 2024
pulisher
Oct 09, 2024

Aditxt faces Nasdaq delisting over share price rule By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 09, 2024

Aditxt faces Nasdaq delisting over share price rule - Investing.com India

Oct 09, 2024
pulisher
Oct 08, 2024

Aditxt Inc: Navigating Market Fluctuations with a 0.18M Market Cap - The InvestChronicle

Oct 08, 2024
pulisher
Oct 08, 2024

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem - Quantisnow

Oct 08, 2024
pulisher
Oct 07, 2024

Aditx Therapeutics stock hits 52-week low at $1.58 - Investing.com India

Oct 07, 2024
pulisher
Oct 07, 2024

Aditx Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com Australia

Oct 07, 2024
pulisher
Oct 07, 2024

Aditxt Inc (ADTX)’s stock price range in the last year - US Post News

Oct 07, 2024

Aditxt Inc Stock (ADTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aditxt Inc Stock (ADTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
HRT FINANCIAL LP
10% Owner
Oct 16 '24
Sale
1.17
25,534
29,875
0
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):